Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04810026
Other study ID # 2020-0068
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 3, 2021
Est. completion date October 26, 2021

Study information

Verified date February 2022
Source UnitedHealth Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to understand the impact of medically tailored meals on health-related biometrics (e.g., glucose time-in-range, waist-hip ratio, cholesterol) and how providing medically tailored meals promotes engagement in diabetes education and drives information-seeking behavior.


Description:

The purpose of this research is to understand the impact of medically tailored meals on health-related biometrics (e.g., glucose time-in-range, waist-hip ratio) and how providing medically tailored meals promotes engagement in diabetes education and drives information-seeking behavior. Secondary purposes are to characterize the relationship between information-seeking behaviors and glycemic control; to characterize the relationship between psychometric survey results and program engagement, biometrics, and information-seeking behaviors; and to understand how meal provision and materials influence program satisfaction and adherence to healthy diabetes-related behaviors.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date October 26, 2021
Est. primary completion date October 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be a patient, employee, or employee dependent at Utica Park Clinic in Oklahoma - Be diagnosed with type 2 diabetes, prediabetes, and/or have an A1c result of 5.7 percent or above - Be above an ideal weight (for example, body mass index [BMI] greater than or equal to 25) - 18 years of age or older - Have UnitedHealthcare insurance for 1 year+ - Have an active e-mail address - Have a smartphone with access to the internet that is compatible with the Dexcom G6 app Exclusion Criteria: - Be undergoing any form of cancer treatment - Be pregnant or breastfeeding - Have allergies to nightshade vegetable (e.g., bell peppers, potatoes, tomatoes) or legumes (e.g., green beans, peas), or tree nuts - Currently taking anti-psychotic medications to control schizophrenia and bipolar disorders, as well as other mental disorders including dementia, major depression, and even drug addiction - Be currently taking insulin - Be currently taking sulfonylureas

Study Design


Intervention

Behavioral:
Education
Healthy-lifestyle and diabetes-related virtual education (text and videos)
Meal delivery
breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
Lifestyle coaching
calls with coach and/or nutritionist, access to Facebook community support group

Locations

Country Name City State
United States OptumLabs Minnetonka Minnesota

Sponsors (1)

Lead Sponsor Collaborator
UnitedHealth Group

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Visits to site Usage stats from website that hosts educational materials, from Week 1 through Week 16 Week 16
Other Percentage of tasks completed Usage stats from website that hosts educational materials, from Week 1 through Week 16 Week 16
Other Number of interactions with lifestyle coach Count of total interactions from Week 1 to Week 12 Week 12
Other Change from baseline in modified Yale Food Addiction Scale score at Week 6, Week 13 modified food addiction scale, compared to responses at baseline, where higher scoring indicate a worse outcome; to meet the food addiction threshold, participants must meet the threshold for either question 6 or 7, and the threshold for 3 or more of the remaining questions Week 0, Week 6, Week 13
Other Change from baseline in abbreviated Medical Outcomes Study Sleep Scale Responses to an abbreviated Medical Outcomes Study Sleep Scale, compared to responses at baseline; with the exception of question 2, higher scores indicate a worse outcome and the range of scores (excluding question 2) is 11 - 65 Week 0, Week 13
Primary Change in mean glucose time in range from baseline at Week 6 Percentage of time estimated glucose value (EGV) from continuous glucose monitor (CGM) is between 70 mg/dL and 180 mg/dL, measured daily with weekly composite results Week 0 and Week 6
Primary Change in mean glucose time in range from baseline at Week 12 Percentage of time estimated glucose value (EGV) from CGM is between 70 mg/dL and 180 mg/dL, measured daily with weekly composite results Week 0 and Week 12
Primary Change in mean glucose time in range from baseline at Week 16 Percentage of time estimated glucose value (EGV) from CGM is between 70 mg/dL and 180 mg/dL, measured daily with weekly composite results Week 0 and Week 16
Secondary Change in CGM-derived glucose features from baseline Average of EGVs, percentage time above and below range (< 70 mg/dL or >180 mg/dL), and glucose variability (standard deviation of EGVs), measured via daily with weekly composite results Week 0, Week 6, Week 12, and Week 16
Secondary Change in blood test results from baseline Difference in measurements of HbA1c, HDL cholesterol, total cholesterol, LDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hs-CRP) obtained from blood tests Week 0, Week 12
Secondary Change in self-reported waist-to-hip ratio waist circumference, hip circumference, self-reported weekly; calculated by dividing the waist circumference by the hip circumference Weekly, Weeks 0-12
Secondary Change in self-reported blood pressure blood pressure, self-reported weekly Weekly, Weeks 0-12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2